JP2024504728A5 - - Google Patents

Info

Publication number
JP2024504728A5
JP2024504728A5 JP2023545206A JP2023545206A JP2024504728A5 JP 2024504728 A5 JP2024504728 A5 JP 2024504728A5 JP 2023545206 A JP2023545206 A JP 2023545206A JP 2023545206 A JP2023545206 A JP 2023545206A JP 2024504728 A5 JP2024504728 A5 JP 2024504728A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504728A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/073808 external-priority patent/WO2022161355A1/en
Publication of JP2024504728A publication Critical patent/JP2024504728A/ja
Publication of JP2024504728A5 publication Critical patent/JP2024504728A5/ja
Pending legal-status Critical Current

Links

JP2023545206A 2021-01-26 2022-01-25 キメラ抗原受容体(car)構築物およびcar構築物を発現するnk細胞 Pending JP2024504728A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141621P 2021-01-26 2021-01-26
US63/141,621 2021-01-26
PCT/CN2022/073808 WO2022161355A1 (en) 2021-01-26 2022-01-25 Chimeric antigen receptor (car) constructs and nk cells expressing car constructs

Publications (2)

Publication Number Publication Date
JP2024504728A JP2024504728A (ja) 2024-02-01
JP2024504728A5 true JP2024504728A5 (cg-RX-API-DMAC7.html) 2025-01-29

Family

ID=81327157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545206A Pending JP2024504728A (ja) 2021-01-26 2022-01-25 キメラ抗原受容体(car)構築物およびcar構築物を発現するnk細胞

Country Status (5)

Country Link
US (1) US20240115607A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284394A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024504728A (cg-RX-API-DMAC7.html)
CN (1) CN117062611A (cg-RX-API-DMAC7.html)
WO (1) WO2022161355A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN117425670A (zh) * 2021-05-19 2024-01-19 细胞编辑有限责任公司 双特异性嵌合抗原受体和表达此类双特异性嵌合抗原受体的基因工程化免疫细胞
CN116286660B (zh) * 2022-12-08 2023-10-03 全球细胞控股(广州)有限公司 一种ipsc-(car)自然杀伤细胞、制备方法及其在肿瘤治疗中的应用
WO2025067205A1 (en) * 2023-09-25 2025-04-03 Nanjing Legend Biotech Co., Ltd. Engineered receptors and methods of use thereof
WO2025140265A1 (en) * 2023-12-26 2025-07-03 Wuxi Biologics (Shanghai) Co., Ltd. Combination of chimeric antigen receptor and dap10 in cell therapy
WO2026003135A1 (en) * 2024-06-27 2026-01-02 Genicity Limited Engineered lymphocytes expressing interleukin-15 and interleukin-21 and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPH0746994B2 (ja) 1984-10-04 1995-05-24 味の素株式会社 発酵法によるl−アミノ酸の製造法
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
JPH07501450A (ja) 1991-11-29 1995-02-16 モンサント カンパニー 環状ジグアニレート代謝酵素
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0672161B1 (en) 1992-11-05 1999-09-22 Xyrofin Oy Recombinant method and host for manufacture of xylitol
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP3709564B2 (ja) 1994-08-30 2005-10-26 味の素株式会社 L−バリン及びl−ロイシンの製造法
JP3966583B2 (ja) 1997-06-23 2007-08-29 協和醗酵工業株式会社 発酵法によるl−アミノ酸の製造法
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
NL2006359C2 (en) 2011-03-08 2012-04-24 Bird Engineering B V Genetically modified cell and process for use of said cell.
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
US9913627B2 (en) * 2013-01-29 2018-03-13 Becton, Dickinson And Company Specimen collection container having a fluid separation chamber
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
AR098743A1 (es) 2013-12-13 2016-06-08 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
RU2751362C2 (ru) * 2014-12-29 2021-07-13 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
CN113862292B (zh) * 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
CA3172801A1 (en) 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
ES2778651T3 (es) 2015-10-09 2020-08-11 Miltenyi Biotec Technology Inc Receptores de antígeno quimérico y métodos de uso
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
AU2018227583B2 (en) * 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
US11905528B2 (en) * 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
CN111886008B (zh) 2017-10-18 2024-05-31 港大科桥有限公司 用于抗mers-冠状病毒治疗的组合物和方法
CN108219004A (zh) * 2018-02-08 2018-06-29 吉林省拓华生物科技有限公司 双特异嵌合抗原受体修饰的t细胞、其制备方法及用途
IL321548A (en) * 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
WO2020055368A2 (en) 2018-09-12 2020-03-19 Istanbul Medipol Universitesi Usage of terpenic coumarin derived molecules in treating viral diseases
AU2019377461A1 (en) * 2018-11-06 2021-05-27 Washington University Chimeric antigen receptor memory-like (CARML) NK cells and methods of making and using same
KR20210137085A (ko) * 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
US20220152110A1 (en) * 2019-03-22 2022-05-19 The Regents Of The University Of California Switchable Chimeric Antigen Receptor-Engineered Human Natural Killer Cells
US20200308248A1 (en) * 2019-03-26 2020-10-01 ST Phi Therapeutics Chimeric Natural Killer Cell Receptors and Method of Using Thereof

Similar Documents

Publication Publication Date Title
EP3472205B1 (en) Chimeric antigen receptor
JP2022109953A5 (cg-RX-API-DMAC7.html)
US20250101080A1 (en) Chimeric antigen receptors and uses thereof
US11578126B2 (en) Chimeric antigen receptor (CAR) comprising a CD19-binding domain
AU2016238583B2 (en) Chimeric antigen receptor
CN112074278B (zh) Bcma-car-t细胞
US11692034B2 (en) CD47-CAR-T cells
JP2022523961A5 (cg-RX-API-DMAC7.html)
JP2024500847A5 (cg-RX-API-DMAC7.html)
US20200255494A1 (en) Cell
HRP20241535T1 (hr) Receptori koji pružaju ciljanu kostimulaciju za adoptivnu staničnu terapiju
EP3471770A1 (en) Tunable chimeric antigen receptors
JP2018523484A (ja) 細胞
JP2002521053A (ja) ヘテロミニ体
CN110114371A (zh) 嵌合抗原受体
TW201841944A (zh) 4-1bbl變異體及包含其之融合蛋白
JP2024544559A5 (cg-RX-API-DMAC7.html)
CN112996819B (zh) 细胞分选系统及使用方法
JP2024504162A5 (cg-RX-API-DMAC7.html)
WO2021168317A1 (en) Inhibitory chimeric receptor architectures
CN114286691B (zh) Cs1-抗体和抗cs1-car-t细胞
CN118302443A (zh) 改善的抗原结合受体
JP2025515995A5 (cg-RX-API-DMAC7.html)
JP2025513855A5 (cg-RX-API-DMAC7.html)
US20220184130A1 (en) Artificial signalling molecule